Early drug development requires manufacturing of Investigational Medicinal Products (IMP) that comply with Good Manufacturing Practice (GMP) systems and processes. PRA Early Development Services (EDS) provides in-house Chemistry, Manufacturing, and Control (CMC) services, including formulation development and real-time manufacture of subject-ready drug products on-site in PRA’s state-of-the-art GMP facilities.
Hepatic Impairment Studies – Early Patient Solutions
PRA Health Sciences’ Early Patient Solutions (EPS) is an established team of highly experienced Phase I professionals dedicated to early phase…
Early Patient Solutions
We provide the infrastructure, technologies, and expertise required to execute early phase patient studies worldwide.
Accelerated Early Clinical Manufacturing
PRA’s Accelerated Early Clinical Manufacturing services provide on-site IMP development and manufacturing, as well as in-house Quality Control lab…